Susan O'Brien
O'Brien, Susan, 1954-
O'Brien, Susan M. 1954-
O'Brien, Susan M.
VIAF ID: 41324176 (Personal)
Permalink: http://viaf.org/viaf/41324176
Preferred Forms
- 200 _ | ‡a O'Brien ‡b Susan M.
-
- 100 1 _ ‡a O'Brien, Susan M. ‡d 1954-
- 100 1 _ ‡a O'Brien, Susan M. ‡d 1954-
-
- 100 1 _ ‡a O'Brien, Susan, ‡d 1954-
-
- 100 0 _ ‡a Susan O'Brien
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Chronic lymphocytic leukemia, c2008: | |
Chronic myelogenous leukemia, version 1.2015. | |
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. | |
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia | |
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia | |
End points to establish the efficacy of new agents in the treatment of acute leukemia. | |
Eradication of minimal residual disease in hairy cell leukemia | |
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia | |
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies | |
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia | |
Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge | |
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia | |
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia | |
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome | |
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency | |
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. | |
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years | |
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit | |
The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment | |
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia | |
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? | |
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation | |
Management of hematologic malignancies | |
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia | |
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. | |
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. | |
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients | |
The role of gemtuzumab ozogamicin in acute leukaemia therapy | |
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells | |
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens | |
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens | |
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis | |
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase | |
Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance | |
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome | |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up | |
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy | |
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy | |
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome |